Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
KEYNOTE-689
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
- NCT03765918 ↗
- Active, not recruiting
- Merck Sharp & Dohme LLC
- Deep
We haven't built an HCP commentary report on KEYNOTE-689 (pembrolizumab and cisplatin in Head and Neck Neoplasms) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on KEYNOTE-689 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 53 | |
| YouTube | 42 | |
| Podcasts | 29 | |
| Bluesky threads | 2 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Head and Neck Neoplasms
- Interventions
- Pembrolizumab 200 mg; Radiotherapy 60 Gray; Radiotherapy 66 Gray; Radiotherapy 70 Gray; Cisplatin 100 mg/m^2
- Arms
- Pembrolizumab + Standard of Care (SOC) · Experimental
- Standard of Care (SOC) · Active comparator
- Enrollment
- 714
- Primary outcomes
- Event-free Survival (EFS)
- EFS in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10
- EFS in Participants With PD-L1 CPS ≥1
- Sponsor
- Merck Sharp & Dohme LLC
- Start
- Dec 17, 2018
- Primary completion
- Jul 25, 2024
- Results posted
- Yes
- Registry record
- NCT03765918 · updated Jul 31, 2026
Publications
linked from the registry- Uppaluri R, Haddad RI, Tao Y, Le Tourneau C, Lee NY, Westra W, Chernock R, Tahara M, Harrington KJ, Klochikhin AL, Brana I, Vasconcelos Alves G, Hughes BGM, Oliva M, Pinto Figueiredo Lima I, Ueda T, Rutkowski T, Schroeder U, Mauz PS, Fuereder T, Laban S, Oridate N, Popovtzer A, Mach N, Korobko Y, Costa DA, Hooda-Nehra A, Rodriguez CP, Bell RB, Manschot C, Benjamin K, Gumuscu B, Adkins D; KEYNOTE-689 Investigators. Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer. N Engl J Med. 2025 Jul 3;393(1):37-50. doi: 10.1056/NEJMoa2415434. Epub 2025 Jun 18. PubMed 40532178